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Effective strategies for preventing human immunodeficiency
virus infection are urgently needed, but recent failures in key
clinical trials of vaccines and microbicides highlight the need
fornewapproaches validated in relevant animalmodels.Here,
we show that 2 new chemokine (C-Cmotif) receptor 5 inhibi-
tors, 5P12-RANTES (regulatedon activation, normalT cell ex-
pressed and secreted) and 6P4-RANTES, fully protect against
infection in the rhesus vaginal challenge model. These highly
potentmolecules,whichare amenable to low-cost production,
represent promising new additions to the microbicides
pipeline.
The HIV/AIDS epidemic produces2.5 million new infections
per year [1], nearly all in the developing world, where women
and young girls aremost at risk. The spread of the epidemicmust
be slowed, and several prevention strategies are being explored.
Despite25yearsofheavy investment, therearecurrentlynoplau-
sibleHIVvaccine candidates. Akey clinical trial recently failed, sug-
gesting that a lengthy series of challenging scientific problemsmust
be solved before promising vaccine strategies can emerge [2]. Top-
ical prevention strategies have fewer conceptual problems and
could reach the clinical proof-of-principle stage sooner than vac-
cines. Such strategies involve substances, generally knownasmicro-
bicides, that have the potential to prevent or reduce the risk of HIV
transmissionwhenapplied to thegenitalmucosabefore intercourse
[3]. However, disappointing results from recent large-scale micro-
bicide trials [4, 5] have underlined the need for new, rationally de-
signed microbicide candidates with in vivo activity validated in an
appropriate animal model [3, 6].
TheHIVcoreceptorCCR5 isa logical target for suchstrategies [3,
7]. Entry inhibitors that block CCR5 have shown promise in the
rhesus vaginal challengemodel [7, 8], possibly themost relevant in
vivo model for preclinical evaluation of topical prevention strate-
gies [6]. In this model, PSC-RANTES, an N-terminally modified
analogue of a natural chemokine ligand of CCR5 [9], has protected
all animals studied (originally 5 of 5 [7] and now 12 of 12 [R.S.V.,
M.M.L.,R.O.,D.M., andO.H., additionalunpublisheddata])when
used at a concentration of 1 mmol/L.
PSC-RANTES is a highly potent entry inhibitor for CCR5-
using HIV. Its inhibitory mechanism involves the durable intra-
cellular sequestration of CCR5 [9]. However, because it contains
nonnatural, noncoded structures, its production requires ex-
pensive chemical synthesis steps, and, despite its promising po-
tency and efficacy, it might be impossible to produce affordably
for the developing world [10].
In the food and detergent industries, microbial fermentation
readily yields multiton quantities of pure, food-grade, good-
manufacturing-practice proteins [11], and a fully recombinant an-
alogue of PSC-RANTES would be amenable to such production
techniques.Usingamodifiedphagedisplay strategy,we successfully
identified 2 such analogues, which we have called 5P12-RANTES
(Q0-[G1-P2-P3-L4-M5-A6-T7-Q8-S9]RANTES/CCL5) and 6P4-
RANTES (Q0-[G1-P2-P3-G4-D5-I6-V7-L8-A9]RANTES/CCL5) [12].
In vitro, both show picomolar anti-HIV potency indistinguishable
fromthatofPSC-RANTES[12].Theaimof thepresent studywas to
compare the efficacy of these 2 new molecules with that of PSC-
RANTES in a standardmacaque vaginal challenge model.
Methods. PSC-RANTES was produced by total chemical
synthesis, as described elsewhere [9]. 5P12-RANTES and 6P4-
RANTES, prepared by total chemical synthesis, were produced
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by Bachem. Before administration, analogues weremade up as 1
mmol/L solutions in PBS.
Challengeexperimentswereperformedunderconditions similar
to those used in other studies [7, 8, 13]. All studies adhered to the
guidelines given in the Guide for the Care and Use of Laboratory
Animals [14] and to the guidelines of the Tulane National Primate
Research Center Institutional Animal Care and Use Committee.
Normal-cycling adult female rhesus macaques (Macacca mulatta)
were treated with a single 30-mg intramuscular injection of depot
medroxyprogesterone acetate (Depo-Provera). After 30–33 days,
they were sedated with Telazol (tiletamine plus zolazepam; Fort
DodgeAnimalHealth) andplaced in ventral recumbencywith hips
elevated; 4 mL of either PBS or 1 mmol/L solutions of chemokine
analogues in PBS was introduced without trauma into the vaginal
vault, using a pliable French catheter. The animals were challenged
30min later with 300TCID50 of simian-human immunodeficiency
virus (SHIV) SF162P3, obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program, in 1mL of
RPMI 1640.
Blood was collected in EDTA tubes every week after chal-
lenge for 70 days. Plasma viral levels were determined by
quantifying simian immunodeficiency virus (SIV) gag RNA
with a real-time reverse-transcription polymerase chain reac-
tion (PCR) assay, as described elsewhere [15]. The assay has a
sensitivity threshold of 5 RNA copies per PCR, or 30 RNA
copies/mL of plasma for the standard volume tested (0.5 mL).
Infection-free status was defined as a consistently undetect-
able plasma viremia for all of the analyses, and it was con-
firmed by monitoring for antibody seroconversion with
Western blot analysis (ZeptoMetrix SIV Western Blot Kit)
[16]. In addition, a PCR assay was performed on peripheral
blood mononuclear cells (PBMCs) to detect proviral ge-
nomes. Genomic DNA was extracted from PBMCs isolated
from EDTA-anticoagulated blood. SIV proviral DNA was
detected by nested PCR using SIVmac-specific gag primers, as
follows:forthefirstround,PF1(5'-AGGAACCAACCACGACGGAG-
3') and PR1 (5'-AAAGGGATTGGCACTGGTGCGAGG-3'; for the
second round, PF2 (5'-TCCGTCTTGTCAGGGAAGAAAGCA-3')
andPR2(5'-ATGCACCAGATGACGCAGACAGTA-3'). First-round
PCR was performed using 0.5–1 g of genomic DNA, with one-
tenth of the product used for the second round.
Results. We compared the in vivo efficacy of 5P12-RANTES
and 6P4-RANTES with that of PSC-RANTES in a standard ma-
caque vaginal challengemodel [7, 8, 13]. Animals received either
PBS or RANTES analogues at 1 mmol/L in PBS, 30 min before
challenge with 300 TCID50 of SHIV162P3. They were thenmon-
itored weekly for plasma viremia for 10 weeks (figure 1). Al-
though 4 of 5 control macaques became infected, all of the
treatedmacaques were completely protected. For each analogue,
protection was significant (P  .05; Fisher’s exact test). Viremia
was not detected at any time; no antiviral antibodies were found
in serumbyWestern blot analysis 70 days after challenge, and no
proviral DNA was detected in PBMCs by PCR 320 days after
Figure 1. Full protection of macaques against vaginal simian-human immunodeficiency virus (SHIV) challenge by intravaginal pretreatment with
recombinant chemokine analogues. Thirty minutes before challenge with 300 TCID50 of SHIV162P3, animals were treated with either PBS or RANTES
analogues at 1 mmol/L. They were then monitored regularly for plasma viremia for 10 weeks.
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challenge. Hence, 5P12-RANTES and 6P4-RANTES fully match
the efficacy of PSC-RANTES in vivo.
Discussion. In addition to being potent, being effective in a
relevant animal model, and presenting no obvious safety issues,
candidate microbicides must also show adequate stability and be
suitable for manufacture at a cost and scale appropriate for world-
wideuse [3,10]. 5P12-RANTESand6P4-RANTESshowpromising
stability at elevated temperatures and low pH and after incubation
with human cervicovaginal lavage samples [17]. Importantly, tak-
ing 5P12-RANTES as an example,we have achieved successful pro-
duction of pure, authentic material via microbial fermentation
(R.O., O.H., H. Gaertner, and F. Cerini, unpublished data).
Wechose to testboth5P12-RANTESand6P4-RANTES,because
they differ slightly in their pharmacological properties and it is not
yet clear which profile would be best for a candidate microbicide.
Although 6P4-RANTES resembles PSC-RANTES in that it is a
CCR5 agonist that induces intracellular sequestration of the recep-
tor, 5P12-RANTES neither internalizes nor (as judged by calcium
flux measurements) activates CCR5 [12]. Receptor internalization
may afford prolonged protection of target cells after a single dose
andprovide a strong barrier to generating resistant escapemutants.
However, CCR5 activation could induce inflammation [18], a
known risk factor for HIV transmission.
Moreworkwillnowberequired todeterminewhichof thesenew
molecules is most suitable for further development. These could
include safety studies in macaques involving chronic exposure of
the vaginal lumen and further efficacy studies using more-virulent
SIVmac isolates. The conclusion of this preliminary study is that
both molecules meet the criteria for addition to the microbicide
pipeline, and priority should be given to evaluating them as prom-
ising topical strategies for the prevention of HIV infection.
References
1. Joint United Nations Programme on HIV-AIDS (UNAIDS) andWorld
Health Organization (WHO). AIDS epidemic update: December 2007.
Geneva: UNAIDS and WHO, 2007.
2. HIV vaccine failure prompts Merck to halt trial. Nature 2007; 449:390.
3. Lederman MM, Offord RE, Hartley O. Microbicides and other topical
strategies to prevent vaginal transmission of HIV. Nat Rev Immunol
2006; 6:371–82.
4. Bolognesi N. AIDS gel’s failure calls prevention approach into question.
Nat Med 2007; 13:230.
5. Cohen J. AIDS research: microbicide fails to protect against HIV. Sci-
ence 2008; 319:1026–7.
6. Grant RM, Hamer D, Hope T, et al. Whither or wither microbicides?
Science 2008; 321:532–4.
7. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV
transmission in rhesus macaques through inhibition of CCR5. Science
2004; 306:485–7.
8. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from
vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell
fusion. Nature 2005; 438:99–102.
9. Hartley O, Gaertner H,Wilken J, et al. Medicinal chemistry applied to a
synthetic protein: development of highly potent HIV entry inhibitors.
Proc Natl Acad Sci USA 2004; 101:16460–5.
10. Moore JP. Topical microbicides become topical. N Engl J Med 2005;
352:298–300.
11. Schafer T, Borchert TW, Nielsen VS, et al. Industrial enzymes. Adv Bio-
chem Eng Biotechnol 2007; 105:59–131.
12. Gaertner H, Cerini F, Kuenzi G, et al. Highly potent, fully recombinant
anti-HIV chemokines: re-engineering a low-costmicrobicide. ProcNatl
Acad Sci USA 2008; 105:17706–11.
13. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small molecule CCR5
inhibitor in macaques to treat simian immunodeficiency virus infection
or prevent simian-human immunodeficiency virus infection. J ExpMed
2003; 198:1551–62.
14. Institute of Laboratory Animal Research, Commission on Life Sciences,
National Research Council. Guide for the care and use of laboratory
animals. Washington, DC: National Academy Press, 1996.
15. Cline AN, Bess JW, Piatak M Jr, Lifson JD. Highly sensitive SIV plasma
viral load assay: practical considerations, realistic performance expecta-
tions, and application to reverse engineering of vaccines for AIDS. JMed
Primatol 2005; 34:303–12.
16. Ling B, Santiago ML, Meleth S, et al. Noninvasive detection of new
simian immunodeficiency virus lineages in captive sooty mangabeys:
ability to amplify virion RNA from fecal samples correlates with viral
load in plasma. J Virol 2003; 77:2214–26.
17. Cerini F, Landay A, Lederman MM, et al. Evaluating the stability of
chemokine-based microbicides. J Acquir Immune Defic Syndr 2008;
49: 472–6.
18. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5
and its role in HIV infection and treatment. JAMA 2006; 296:815–26.
BRIEF REPORT ● JID 2009:199 (15 May) ● 1527
